Media Center

Archives: Press Release

Entasis Therapeutics Presents Data on Third Drug Candidate, ETX0282, an Orally Available, Extended-Spectrum Βeta-lactamase Inhibitor, at ASM Microbe 2017

Presentations Also Highlight the Activity of ETX2514 Combinations against Acinetobacter and Pseudomonas   WALTHAM, Mass. — June 7, 2017 — Entasis Therapeutics, a leader in the discovery and development of breakthrough anti-infective products, delivered multiple presentations at the American Society of Microbiology (ASM) Microbe 2017 Conference, June 1-5 in New Orleans, Louisiana. The presentations featured […]

Entasis Therapeutics to Present at Upcoming June 2017 Investor Conferences

WALTHAM, Mass. — May 31, 2017 — Entasis Therapeutics, a leader in the discovery and development of breakthrough anti-infective products, today announced that CEO, Manos Perros will present at two upcoming investor conferences in June, the Jefferies Global Healthcare Conference taking place in New York, NY on June 6 to 9, and the JMP Securities […]

Entasis Therapeutics to Present Data on ETX2514 and Entasis’ Third Drug Candidate, ETX0282, at ASM Microbe 2017

WALTHAM, Mass. — May 22, 2017 — Entasis Therapeutics, a leader in the discovery and development of breakthrough anti-infective products, today announced multiple presentations at the American Society of Microbiology (ASM) Microbe 2017 Conference, taking place June 1-5 in New Orleans, LA. Presentations will include data on Entasis’ lead program, ETX2514, as well as an […]

Entasis Therapeutics to Present Data at 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

WALTHAM, Mass. — April 21, 2017 — Entasis Therapeutics, a leader in the discovery and development of breakthrough anti-infective products, today announced two oral presentations at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), which is being held April  22 – 25 in Vienna, Austria. Both presentations will highlight the preclinical profile […]

Entasis Appoints Mike Gutch as Chief Financial Officer and Chief Business Officer

WALTHAM, Mass. — April 10, 2017 — Entasis Therapeutics Inc., a company focused on the discovery and development of breakthrough anti-infective products, today announced the appointment of Mike Gutch, Ph.D., as Chief Financial Officer and Chief Business Officer. Dr. Gutch has extensive experience as a business executive in the biotechnology and pharmaceutical industries as well […]

Entasis Therapeutics Announces Partnership with CARB-X to Support Development of Oral, Gram-negative Program

Entasis Awarded up to $6.3MM to Develop its Oral Agent for the Treatment of Multi-drug Resistant Gram-negative Infections, Including Those Caused by Carbapenem-Resistant Enterobacteriaceae (CRE) WALTHAM, Mass. — March 30, 2017 — Entasis Therapeutics Inc., a company focused on the discovery and development of breakthrough anti-infective products, today announced that it has entered into a […]

Entasis Therapeutics Names Greg Norden, Former Senior Vice President and Chief Financial Officer of Wyeth, to its Board of Directors

WALTHAM, Mass. — November 29, 2016 — Entasis Therapeutics, a company focused on the discovery and development of breakthrough anti-infective products, announced today the appointment of Greg Norden to the company’s Board of Directors. “Greg is an outstanding leader in our industry, and I am delighted to welcome him to our Board,” said Manos Perros, […]

Entasis Therapeutics to Present Data at IDWeek on ETX2514SUL, a Novel Drug Targeting Multidrug-Resistant Acinetobacter baumannii Infections

Data also to be Presented on EXT0914, a Novel Drug Targeting Gonorrhea WALTHAM, Mass. — October 28, 2016 — Entasis Therapeutics, a leader in the discovery and development of breakthrough anti-infective products, today announced that it will present four posters at IDWeek 2016™, which is being held from October 26 – 30 in New Orleans. […]

Entasis Announces Initiation of Phase I Clinical Trial of ETX2514

ETX2514 in Combination with Sulbactam is Being Developed for the Treatment of Serious Drug-Resistant Hospital Infections WALTHAM, Mass. — October 26, 2016 — Entasis Therapeutics, a company focused on the discovery and development of breakthrough anti-infective products, today announced initiation of a Phase 1 clinical study of ETX2514. The study will evaluate the safety, tolerability […]

Entasis Announces Positive Phase 2 Data of ETX0914 for the Treatment of Gonorrhea

Validates Company’s Pathogen-targeted Discovery and Development Platform WALTHAM, Mass. — September 21, 2016 — Entasis Therapeutics, a company focused on the discovery and development of breakthrough anti-infective products, today announced that data from a Phase 2 study of ETX0914, the Company’s novel oral antibiotic compound, will be presented at the 2016 STD Prevention Conference in […]